1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Poster Jianing HouDachuang CaoLei Qian2015 год

Poster
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Objectve: According to the AACE guideline, patients with entry HbA 1c >9% and symptoms can start insulin therapy, and according to the Chinese premixed insulin consensus, patients with HbA 1c ≥9% who have inadequate glycemic control on two or more oral antihyperglycemic drugs (OADs) can start premixed insulin twice daily.This analysis compared the efficacy of lispro mix 75/25 (LM75/25) bid versus glargine QD by baseline HbA 1c subgroup (<9% or ≥9%) to assess these two starter insulin strategies.Methods: In the DURABLE trial, insulin-naïve patients with type 2 diabetes, aged 30-80 years and with HbA 1c >7% on at least two OADs for 90 days were randomized to receive twice daily LM75/25 or daily glargine with the continuation of prestudy OADs for 6 months in the initiation phase and for 24 months in the maintenance phase if HbA 1c <7.0% is reached in the initiation phase (Buse et al.Diabetes care.2009, 32(6): 1007; 2011, 34(2): 249).This subgroup analysis included randomized patients with at least one non-missing HbA 1c measurement (n = 1941 in the initiation phase and 871 in the maintenance phase).The change in HbA 1c from baseline to the month 6 endpoint (LOCF) and the month 30 endpoint (LOCF) were analysed by ANCOVA with the treatment, country, baseline HbA 1c subgroup, and treatment*baseline A1c subgroup used as covariates.The percentage of patients reaching the HbA 1c target was assessed using the Cochran-Mantel-Haenszel test and controlling for country.Results: At the initiation phase (month 6) endpoint, LM75/ 25 resulted in greater HbA 1c reduction in both subgroups (baseline HbA 1c < 9%: LSM ± SE = À1.19 ± 0.05% vs À1.02 ± 0.05%, p = 0.014; baseline HbA 1c ≥ 9%: À2.58 ± 0.06% vs À2.42 ± 0.06%, p = 0.026).LM75/25 also resulted in a higher percentage of patients reaching the target of HbA 1c <7% in the baseline HbA 1c <9% group (60.4% vs 51.4%, p = 0.002) and a numerically but not significantly higher percentage of patients reaching the target in the baseline HbA 1c ≥9% group (32.8% vs 28.2%, p = 0.170).At the maintenance phase (month 30) endpoint, LM75/25 resulted in greater HbA 1c reduction in both subgroups (baseline HbA 1c < 9%: À0.97 ± 0.06% vs À0.80 ± 0.07%, p = 0.032; baseline HbA 1c ≥ 9%: À2.67 ± 0.08% vs À2.35 ± 0.09%, p = 0.003).LM75/25 also resulted in a numerically but not significantly higher percentage of patients reaching the target of HbA 1c < 7% in both subgroups (baseline HbA 1c < 9%: 50.0%vs 47.6%, p = 0.466; baseline HbA 1c ≥ 9%: 34.2% vs 23.9%, p = 0.056).Conclusion: LM75/25 bid resulted in greater HbA 1c reduction and a higher percentage of patients reaching the target of HbA 1c <7% than did glargine QD in patients with baseline HbA 1c of either <9% or ≥9%.Patients with baseline HbA 1c <9% also benefit from receiving LM75/ 25 bid as starter insulin.
Год издания: 2015
Авторы: Jianing Hou, Dachuang Cao, Lei Qian, Lan Shen, Kan Wang, Yun Chen, Andrea Leith, Steven Babineaux, Tingting Tan, Chao Deng, Zhihui Ren, Yufei Xiang, Chuqing Cao, Zhiguang Zhou, Qing Su, Pengfei Li, Wenying Yang, Min Long, Hongting Zheng, Donna Zhang, Georg T. Wondrak, Shuang Guo, Li Ping, Cong Liu, Cuilin Zhang, Fang Hui, Yukai Li, Lin Zhou, Ruhua Guan, Yanfeng Zhen
Издательство: Wiley
Источник: Diabetes/Metabolism Research and Reviews
Другие ссылки: Diabetes/Metabolism Research and Reviews (PDF)
Diabetes/Metabolism Research and Reviews (HTML)
PubMed (HTML)